Investigational Seladelpar Demonstrates Significant Improvements in Liver Disease Progression and Reduced Itching in Primary Biliary Cholangitis

- 70% of Patients Receiving Seladelpar 10mg Achieved the Clinically Meaningful Composite Endpoint and 37% Achieved ALP Normalization at 12 Months -


- Reduction in Patient-Reported Pruritus was...

Related Keywords

United Kingdom ,Washington ,United States ,Foster City ,California ,Merdad Parsey ,Gilead Sciences In Liver Disease ,Gilead Sciences Inc ,Regulatory Agency ,Nasdaq ,Gilead Company ,Exchange Commission ,Cymabay Therapeutics Inc ,Drug Administration ,University Of Miami ,European Medicines Agency ,Gilead Sciences ,Cymabay Therapeutics ,Presidential Plenary ,Digestive Disease ,Cynthia Levy ,Chief Medical Officer ,New Drug Application ,Child Pugh ,United Kingdom Medicines ,Primary Biliary Cholangitis ,Interim Results ,Bay Therapeutics ,Private Securities Litigation Reform Act ,Quarterly Report ,Liver Disease ,